Launch of the Initial Public Offering

September 17, 2018

MedinCell launches its initial public offering on the regulated market of Euronext in Paris
• Capital increase of approximately €34.1m, which may be increased to a maximum of approximately €45.1m if the extension clause and the over-allotment option are fully exercised1
• Indicative Offering Price range: €7.25 to €9.25 per share
• Closing of Open Price Offering: September 26, 2018 (at 5.00 pm (CEST) for subscriptions placed at counters and 8.00 pm (CEST time) for online subscriptions)
• Closing of the Global Placement: September 27, 2018 (at 12.00 pm (CEST time))
• Settlement-delivery of the Offering: October 1st, 2018
• Beginning of trading of the MedinCell shares: October 2nd 2018
• Eligibility to PEA-PME
• Strong support from institutional investors to the operation: subscription commitments from CM-CIC Innovation up to €4.7m and BNP Paribas Développement of €3m

1 Based on the median point of the indicative price range

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.